Ajai Chari, MD, of Mount Sinai School of Medicine, discusses results from the MonumenTAL-1 phase I/II study of talquetamab. Patients with multiple myeloma receiving BCMA-targeted therapies are at high risk of infectious complications. Gary Schiller, MD, of the University of California, Los Angeles, discusses the STOMP study. Blood Cancers Today Editor-in-Chief Sagar Lonial, MD, FACP, discusses novel therapies in myeloma, MRD data, and more. Thomas Martin, MD, discusses advances in frontline treatments for multiple myeloma, the need for novel agents, and more. Patients with heavily pretreated multiple myeloma who received bispecific CAR T-cells had an OS rate of 83.9%. Sandy Wong, MD, discusses results from a phase I first-in-human study of alnuctamab in patients with relapsed/refractory MM. The phase I UNIVERSAL trial showed allogeneic CAR-T therapy led to “significant and durable responses” in patients with ... Use of drugs with alternative modes of action may be needed to overcome persistent MRD positivity in myeloma. Selinexor combinations had moderate efficacy in real-world patients with relapsed or refractory multiple myeloma. A new study presented at the 2022 ASH Annual Meeting identified causes of the increased myeloma risk in Black Americans. BCMA-directed CAR-T led to a CR in 75% in relapsed/refractory multiple myeloma who received allogeneic HSCT. A new study suggests many interventional phase III clinical trials in myeloma didn't clearly define high-risk disease. More genetic information is needed to investigate the link between racial ancestry and outcomes in multiple myeloma.